A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This was an exploratory study to determine whether escalating doses of RAD001 (everolimus)
were safe and effective in patients with Lymphangioleiomyomatosis